clinical hematology News
-
HORIBA Medical and NOEMALIFE signed a Worldwide Distribution Agreement for a dedicated version of the HALIA middleware
HORIBA Medical is pleased to announce the press release of the worldwide distribution agreement signed between NOEMALIFE (www.noemalife.com/en/) and HORIBA Medical for a dedicated version of the HALIA middleware. The HORIBA Medical middleware is a new product in our IT products range including already our data manager, ABX Pentra ML. This middleware will be the link between all instruments and ...
-
Amerigo Scientific Introduces the Launch of Polystreptavidin 350
Amerigo Scientific, a distribution company focused on providing critical products and services to the biomedical and life science research communities, now introduces Polystreptavidin 350 for applications in lateral flow, ELISA or CLIA. Diagnosis is a key enabler of universal health coverage and the first line of defense against the spread of many diseases. From rapid treatment and combating ...
-
Lung Therapeutics Announces Appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development
Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary diseases and conditions, today announced the appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development. In this critical role, she will be responsible for guiding Lung Therapeutics’ clinical programs and will serve as a key member of the ...
-
Thermo Fisher Scientific Introduces Hematology-Oncology Portfolio for Ion Torrent Genexus System
In hematology oncology, it is critically important to understand the genetics driving acute malignancies to quickly determine how best to address the disease. Today, Thermo Fisher Scientific announces a new portfolio of hematology-oncology assays for the Ion Torrent Genexus System* designed to enable a future in which turnaround times for next-generation sequencing (NGS) results can be reduced to ...
-
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been initiated and will begin recruiting soon Neurona Therapeutics, a clinical-stage biotherapeutics ...
-
Thermo Fisher Scientific Opens Call for Grant Proposals to Fund Clinical Research in Hematology-oncology
To support clinical research needs using next-generation sequencing (NGS), Thermo Fisher Scientific today announced it is accepting new submissions for its Oncomine Clinical Research Grant. The latest call for proposals aims to provide funding for clinical research programs that leverage NGS in solid tumors and hematology-oncology applications. The Oncomine Clinical Research Grant awards ...
-
Optimizing Monoclonal Antibody Production: Temperature And Osmolality’s Impact, Upcoming Webinar Hosted By Xtalks
In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies. Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant. The featured speaker will discuss how temperature and osmolality ...
-
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of prostate cancer and is currently in ...
-
Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced real-world data on Endari®, the company’s prescription-grade L-glutamine oral powder, in preventing acute complications from sickle cell disease (SCD) and hemolysis in pediatric and adult patients in French Guiana and Qatar. The data ...
-
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ...
-
Affimed Establishes Scientific Advisory Board
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology Scientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerging technologies Heidelberg, Germany, June 30, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or ...
By Affimed GmbH
-
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
Study explores opportunity to shift from clinic to home instillation of this promising non-surgical treatment Potential to transform care and access to treatment for this growing patient population UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that the ...
-
Novel Securement Device Making Inroads
AVA Scientific Meeting 2019 highlights key opportunities for improvement in vascular access from process bundles to emerging new products Introduction Acknowledgment of the importance of the vascular access nurse and team were obvious at this year’s Association for Vascular Access (AVA) Annual Scientific meeting. When Ramzy Nasrallah took over as CEO for the Association of Vascular Access ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you